Molecular Biology Enzymes & Kits & Reagents Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Molecular Biology Enzymes & Kits & Reagents Market projected to be worth USD 48.21 billion by 2030.
According to SPER Market Research, the Molecular Biology Enzymes & Kits & Reagents Market estimated to reach USD 48.21 billion by 2030 with a CAGR of 13.6%. Amplified research, investments, increasing number of genome projects, technological advancement in the life science industry, and growing incidence of genetic disorders; are the fuels for the escalation of the market.
Impact of COVID-19 on the Molecular Biology Enzymes & Kits & Reagents Market
The outbreak of COVID-19 gives a positive impact to the expansion Molecular Biology Enzymes & Kits & Reagents Market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Material, By Technique, By Application, By End-Users, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered ADS Biotec Inc., Agilent, Aldevron, Bio Basic, Bio-Rad Laboratories, Inc.¸Genekam Biotechnology, Goldsite Diagnostics Inc., Hangzhou Matridx Biotechnology Co. Ltd., Illumina, Integrated DNA Technologies, Inc., Jena Bioscience, LGC Biosearch Technologies, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, New England Biolabs, NZYTech, Promega, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation
Driver: increasing number of genome projects
The increasing numeral of genome projects globally, tied with dipping genetic analysis costs; leads to advancement in research in diverse fields like; personalized medicine, microbial genetic, disease treatment. This research need the use of molecular biology enzymes and reagents, consequently impel the expansion of this molecular biology enzymes and kits & reagents market.
Restraints: restricted reimbursements for genetic testing
The inflexible reimbursement policy is the restraints to this market.
Opportunity: Research & Development investments offer significant opportunities for the market
Increase in the funds & grants from the government, advancement in the genomic technological facade, investments in research & development have vast opportunities for this market.
Molecular Biology Enzymes & Kits & Reagents Market, By Product:
Based on the Product, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Kits & Reagents, Enzymes, Polymerases, Ligases, Restriction Endonucleases, Reverse Transcriptases, Other Enzymes.
Molecular Biology Enzymes & Kits & Reagents Market, By Application:
Based on the Application, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology, Other Applications.
Molecular Biology Enzymes & Kits & Reagents Market, By End User:
Based on the End-Users, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Academic & Research Institutes, Pharmaceutical & Biotechnology companies, Hospitals & Diagnostic Centers, Other End Users.
Molecular Biology Enzymes & Kits & Reagents Market, By Region:
North America dominates the biggest share of this market; this is due to the increase in funding of translational and clinical research, increasing the figure of pharmaceutical and biotechnology companies, rising investments in research projects in Canada favourable reimbursement scenario.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER’s internal database
- 2.1.4 Premium insight from KOL’s
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Molecular Biology Enzymes & Kits & Reagents Market
- 5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER’S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4. Heat map analysis
- 6. Molecular Biology Enzymes & Kits & Reagents Market, By Product, 2019-2030 (USD Million)
- 6.1. Kits & Reagents
- 6.2. Enzymes
- 6.3. Polymerases
- 6.4. Ligases
- 6.5. Restriction Endonucleases
- 6.6. Reverse Transcriptases
- 6.7. Other Enzymes
- 7. Molecular Biology Enzymes & Kits & Reagents Market, By Application, 2019-2030 (USD Million)
- 7.1. PCR
- 7.2. Sequencing
- 7.3. Cloning
- 7.4. Epigenetics
- 7.5. Restriction Digestion
- 7.6. Synthetic Biology
- 7.7. Other Applications
- 8. Molecular Biology Enzymes & Kits & Reagents Market, By End User, 2019-2030 (USD Million)
- 8.1. Academic & Research Institutes
- 8.2. Pharmaceutical & Biotechnology companies
- 8.3. Hospitals & Diagnostic Centers
- 8.4. Other End Users
- 9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)
- 9.1. North America
- 9.1.1. United States
- 9.1.2. Canada
- 9.1.3. Mexico
- 9.2. Europe
- 9.2.1. Germany
- 9.2.2. United Kingdom
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
- 9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia-Pacific
- 9.4. South America
- 9.4.1. Brazil
- 9.4.2. Argentina
- 9.4.3. Rest of South America
- 9.5. Middle East & Africa
- 9.5.1. Kingdom of Saudi Arabia
- 9.5.2. United Arab Emirates
- 9.5.3. Rest of Middle East & Africa
- 10. Company Profiles
- 10.1. ADS Biotec Inc.
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
- 10.2. Agilent
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
- 10.3. Aldevron
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
- 10.4. Bio Basic
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
- 10.5. Bio-Rad Laboratories Inc.
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
- 10.6. Genekam Biotechnology
- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments
- 10.7. Goldsite Diagnostics Inc.
- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments
- 10.8. Hangzhou Matridx Biotechnology Co. Ltd.
- 10.8.1. Company details
- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
- 10.9. Illumina
- 10.9.1. Company details
- 10.9.2. Financial outlook
- 10.9.3. Product summary
- 10.9.4. Recent developments
- 10.10. Integrated DNA Technologies, Inc.
- 10.10.1. Company details
- 10.10.2. Financial outlook
- 10.10.3. Product summary
- 10.10.4. Recent developments
- 10.11. Jena Bioscience
- 10.11.1. Company details
- 10.11.2. Financial outlook
- 10.11.3. Product summary
- 10.11.4. Recent developments
- 10.12. LGC Biosearch Technologies
- 10.12.1. Company details
- 10.12.2. Financial outlook
- 10.12.3. Product summary
- 10.12.4. Recent developments
- 10.13. Lucigen Corporation
- 10.13.1. Company details
- 10.13.2. Financial outlook
- 10.13.3. Product summary
- 10.13.4. Recent developments
- 10.14. Merck
- 10.14.1. Company details
- 10.14.2. Financial outlook
- 10.14.3. Product summary
- 10.14.4. Recent developments
- 10.15. MoBiTec GmbH
- 10.15.1. Company details
- 10.15.2. Financial outlook
- 10.15.3. Product summary
- 10.15.4. Recent developments
- 10.16. Molecular Biology Resources
- 10.16.1. Company details
- 10.16.2. Financial outlook
- 10.16.3. Product summary
- 10.16.4. Recent developments
- 10.17. New England Biolabs
- 10.17.1. Company details
- 10.17.2. Financial outlook
- 10.17.3. Product summary
- 10.17.4. Recent developments
- 10.18. NZYTech
- 10.18.1. Company details
- 10.18.2. Financial outlook
- 10.18.3. Product summary
- 10.18.4. Recent developments
- 10.19. Promega
- 10.19.1. Company details
- 10.19.2. Financial outlook
- 10.19.3. Product summary
- 10.19.4. Recent developments
- 10.20. QIAGEN
- 10.20.1. Company details
- 10.20.2. Financial outlook
- 10.20.3. Product summary
- 10.20.4. Recent developments
- 10.21. Randox
- 10.21.1. Company details
- 10.21.2. Financial outlook
- 10.21.3. Product summary
- 10.21.4. Recent developments
- 10.22. Roche
- 10.22.1. Company details
- 10.22.2. Financial outlook
- 10.22.3. Product summary
- 10.22.4. Recent developments
- 10.23. Takara Bio
- 10.23.1. Company details
- 10.23.2. Financial outlook
- 10.23.3. Product summary
- 10.23.4. Recent developments
- 10.24. Thermo Fisher
- 10.24.1. Company details
- 10.24.2. Financial outlook
- 10.24.3. Product summary
- 10.24.4. Recent developments
- 10.25. Zymo Research Corporation
- 10.25.1. Company details
- 10.25.2. Financial outlook
- 10.25.3. Product summary
- 10.25.4. Recent developments
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook